MYOV

The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: * Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 1, 2020 at 4:45 p.m. Eastern time. Lynn Seely, M.D., chief executive officer of Myovant Sciences, Inc., and Frank Karbe, president and chief financial officer of Myovant Sciences, Inc., will participate in a webcast presentation. Management will also participate in virtual one-on-one investor meetings on December 1. * Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation by Dr. Seely will be available at 10 a.m. Eastern time today on the investor relations page of Myovant’s website, investors.myovant.com. Management will participate in virtual one-on-one investor meetings on December 3, 2020. The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.About Myovant Sciences Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.Investor Contact: Ryan Crowe Vice President, Investor Relations Myovant Sciences, Inc. investors@myovant.comMedia Contact: Albert Liao Director, Corporate Communications Myovant Sciences, Inc. media@myovant.com

We feel now is a pretty good time to analyse Myovant Sciences Ltd.'s (NYSE:MYOV) business as it appears the company...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining

Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) -19%, Zhongchao (ZCMD) -14%, IMAC Holdings (IMAC) -14%.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)

Shares of Myovant Sciences (NYSE:MYOV) rose 0.2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 5.06% over the past year to ($0.75), which missed the estimate of ($0.73).Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $290,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Myovant Sciences hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Nov 12, 2020View more earnings on MYOVTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/mkxeraxuTechnicals Company's 52-week high was at $23.04Company's 52-week low was at $5.39Price action over last quarter: down 0.84%Company Profile Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 12, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Myovant Sciences (NYSE:MYOV) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.73) by 2.74 percent. This is a 5.06 percent increase over losses of $(0.79) per share from